Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Michael Hallek, MD

Blood (2015) 126 (23): 2934.

https://doi.org/10.1182/blood.V126.23.2934.2934

Published: 2015

Journal Articles

Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)

Natali Pflug, MD, Georg Hopfinger, MD, Paula Cramer, MD, Alexandra Schrader, PhD, Nicole Weit, PhD, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, MD, Thorsten Zenz, MD, Jan Duerig, MD, Jasmin Bahlo, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Anna-Maria Fink, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Marco Herling, MD

Blood (2014) 124 (21): 1999.

https://doi.org/10.1182/blood.V124.21.1999.1999

Published: 2014

Journal Articles

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Raymonde Busch, Natali Pflug, MD, Sebastian Boettcher, MD, Dirk Winkler, MD, Andreas Buehler, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Myriam Mendila, MD, Michael K. Wenger, MD, Hartmut Doehner, MD, Michael Kneba, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 977.

https://doi.org/10.1182/blood.V118.21.977.977

Published: 2011

Journal Articles

Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Anna-Maria Fink, MD, Raymonde Busch, Dipl.-Math., Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Natali Pflug, MD, Friederike Schubert, Hartmut Döhner, MD, Michael Rieger, MD, Michael Kneba, MD, PhD, Jiri Mayer, MD, Michael Hallek, MD, Kirsten Fischer, MD

Blood (2011) 118 (21): 2863.

https://doi.org/10.1182/blood.V118.21.2863.2863

Published: 2011

Journal Articles

Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials

Jasmin Bahlo, Natali Pflug, MD, Thomas Elter, MD, Kathrin Bauer, MD, Barbara Eichhorst, MD, Manuela Bergmann, MD, Raymonde Busch, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 2831.

https://doi.org/10.1182/blood.V118.21.2831.2831

Published: 2011

Journal Articles

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Natali Pflug, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Dirk Winkler, MD, Andreas Buehler, MD, Myriam Mendila, MD, Michael Wenger, MD, Hartmut Dohner, MD, Stephan Stilgenbauer, M.D., Michael Hallek, MD, Kirsten Fischer, MD

Blood (2010) 116 (21): 918.

https://doi.org/10.1182/blood.V116.21.918.918

Published: 2010

NARROW

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Email alerts

ASH Publications

American Society of Hematology

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only